EGFR and urinary bladder cancer: As a clinical consequence, ERBB pathway inhibition may have limited overall efficacy in non-squamous urothelial tumor cells relieving the pathway repression which may explain why unselected clinical trials failed to demonstrate the clinical significance of EGFR inhibition in bladder cancer so far [34, 35].